Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer
October 06 2016 - 05:00PM
Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has
appointed R. Alberto Avendano, M.D., as the Company’s Chief Medical
Officer.
Dr. Avendano brings to Osiris his expertise in medical education
and communication, academic and industry clinical research,
pharmacovigilance and regulatory affairs. In his role as
Chief Medical Officer, Dr. Avendano will manage and oversee the
continued growth of the Company’s Medical Affairs and Clinical
Operations, act as the Company’s medical spokesperson, and
participate in development of clinical programs for the Company’s
products and technologies.
“Alberto brings a wealth of managerial and life sciences
expertise to Osiris during an important time in our company’s
growth,” said David A. Dresner, Interim CEO of Osiris.
“Alberto will bridge our research and development team to our
marketing team, furthering our commitment to help patients both
today and into the future, as we continue to launch innovative
therapies into the regenerative medicine space.”
Dr. Avendano received his license to practice medicine almost 30
years ago. From June 2013 until joining Osiris, Dr. Avendano
served as the Medical Director for Indivior Inc. (previously
Reckitt Benckisser Pharmaceuticals). Prior to joining
Indivior, Dr. Avendano served in a variety of medical director and
research positions, most recently as Associate Medical Director at
EMD Serono, Inc.
Osiris welcomes Dr. Avendano as the newest member of the
team.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a
world leader in researching, developing and marketing regenerative
medicine products that improve health and lives of patients and
lower overall healthcare costs. Having developed the world's first
approved stem cell drug, the company continues to advance its
research and development in biotechnology by focusing on innovation
in regenerative medicine - including bioengineering, stem cell
research and viable tissue based products. Osiris has achieved
commercial success with products in orthopaedics, sports medicine
and wound care, including BIO4®, Cartiform®, Grafix® , TruSkinTM
and StravixTM. Osiris, Grafix, and Cartiform are registered
trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are
trademarks of Osiris Therapeutics, Inc. BIO4® is a trademark of
Howmedica Osteonics Corp. More information can be found on the
company's website, www.Osiris.com. (OSIR-G).
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include statements about our
expectations, beliefs, plans, objectives, intentions, assumptions
and other statements that are not historical facts. Words or
phrases such as "anticipate," "believe," "continue," "ongoing,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project" or similar words or phrases, or the negatives
of those words or phrases, may identify forward-looking statements,
but the absence of these words does not necessarily mean that a
statement is not forward-looking. Examples of forward-looking
statements may include, without limitation, statements regarding
any of the following: the outcome of the NASDAQ listing
qualification deficiency process, including the ability of the
Company to successfully maintain its NASDAQ listing; the outcome of
the restatements, including the materiality, significance, nature,
subject matter, timing or quantitative effects of the Company's
restated financial statements; the timing of the transition to a
new independent registered public accounting firm; the completion
of the audit of the Company's 2015 financial statements; and the
timing of the filing of the Company's 2015 Form 10-K, Q1 2016 Form
10-Q and Q2 2016 Form 10-Q. Forward-looking statements are subject
to known and unknown risks and uncertainties and are based on
potentially inaccurate assumptions that could cause actual results
to differ materially from those expected or implied by the
forward-looking statements. Our actual results could differ
materially from those anticipated in forward-looking statements for
many reasons, including the factors described in the section
entitled "Risk Factors" in our Annual Report on Form 10-K and other
Periodic Reports filed on Form 10-Q, with
the SEC. Accordingly, you
should not unduly rely on these forward-looking statements. We
undertake no obligation to publicly revise any forward-looking
statement to reflect circumstances or events after the date of this
press release or to reflect the occurrence of unanticipated
events.
For additional information, please contact:
Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Mar 2023 to Mar 2024